In a report released today, Irina Rivkind Koffler from Mizuho Securities maintained a Buy rating on Bausch Health Companies Inc (BHC), with a price target of $45. The company’s shares closed yesterday at $22.88.
According to TipRanks.com, Koffler is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -4.4% and a 32.5% success rate. Koffler covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries Limited, Assertio Therapeutics Inc, and Eagle Pharmaceuticals Inc.
Currently, the analyst consensus on Bausch Health Companies Inc is a Moderate Buy with an average price target of $32.38, representing a 41.5% upside. In a report issued on June 11, Barclays also initiated coverage with a Buy rating on the stock with a $28 price target.
See today’s analyst top recommended stocks >>
Based on Bausch Health Companies Inc’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $52 million. In comparison, last year the company had a GAAP net loss of $2.69 billion.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Bausch Health Cos., Inc. engages in the development, manufacture, and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products.
Read More on BHC:
